Gapping up
In reaction to strong earnings/guidance: MLNX +13.9%, COH +7%, NSPH +6.5%, (also announced that it has received a warning letter from the FDA resulting from inspections of its facility in Northbrook, Illinois by the FDA's Chicago District Office that occurred in March 2014), CTXS +6.4%, (also announced the implementation of a restructuring program designed to increase strategic focus and operational efficiency), NOW +6.4%, FLEX +6%, KATE +5.1% (announces plan to focus investment on kate spade new york; guides FY14 and FY15), EXTR +4.3%, AZPN +4.2%, (light volume), DOW +4.2%, DEO +4%, CAVM +3.8%, DB +3.8%, RDY +3.4%, LVS +3.2%, ISIL +3.2%, (light volume), PENN +3.2%, SHOR +3.1%, CMPR +2.6%, POT +2.6%, CL +2.6%, HAR+2.5%, SWK +2.3%, HP +2.2%, F +2%, BEAV +1.7%, BX +1.6%, CRR +1.5%, VLO +1.4%, MEOH +1.3%, VAR +1.2%, CHKP +1.2%, HOLX +1.1%, SSLT +1.1%, GFF +1%, FLS +0.9%, MD +0.9%, MJN +0.9%, CELG +0.9%, PSX +0.9%, RCI +0.8%, JBLU +0.8%
Other news: XNCR +27.1% (eports top-line XmAb5871 Phase 1b/2a results; showing promising clinical activity in Rheumatoid Arthritis), BLDP +10.4% (wins European Union funding for 21 fuel cell buses), VVUS +6.4% (European Commission has amended the marketing authorization for SPEDRA), PSTI +5.9% (cont strength), NBG +5.8% (rebounding after recent weakness), CBRX+5.3% (Chairman Stephen G. Kasnet does not intend to stand for reelection to the Board when his current term expires at the next annual shareholder meeting), BXE +4.3% (updated 2015 net capital budget and operational outlook), ANTH +3.6% (entered into Subscription Agreements with Zenyaku Kogyo and Amgen (AMGN) with respect to a registered direct offering of ~3.2 mln shares of the Company's common stock), MCD +3% (Announced that Don Thompson will retire as President, CEO, and as a member of the Board, effective March 1; Board has elected Steve Easterbrook to replace Thompson as President and CEO), AVP +2.7% (named James S. Scully Chief Financial Officer), FXCM +2.5% (cont pre-mkt vol), SLXP +1.3% (provides update on Audit Committee review; aggregate impact of errors on net product revenue and net income over all previously reported periods affected by the restatements is a decrease of approximately $20.7 mln and $11.9 mln, respectively), MX +1.1% (updates timeline for restatement; expects to file late quarterly and annual reports during the week of February 9, 2015, but no later than February 13, 2015), AZN +1% (announces four research collaborations aimed at harnessing the power of CRISPR), RDHL +0.9% (provides update on progress with RHB-104 ongoing Phase III program)
Analyst comments: TI +3.7% (added to Focus list at Goldman), CYOU +1.9% (upgraded to Overweight from Underweight at HSBC ), AAPL +0.5% (target raised to $135 from $125 at Argus)
In reaction to strong earnings/guidance: MLNX +13.9%, COH +7%, NSPH +6.5%, (also announced that it has received a warning letter from the FDA resulting from inspections of its facility in Northbrook, Illinois by the FDA's Chicago District Office that occurred in March 2014), CTXS +6.4%, (also announced the implementation of a restructuring program designed to increase strategic focus and operational efficiency), NOW +6.4%, FLEX +6%, KATE +5.1% (announces plan to focus investment on kate spade new york; guides FY14 and FY15), EXTR +4.3%, AZPN +4.2%, (light volume), DOW +4.2%, DEO +4%, CAVM +3.8%, DB +3.8%, RDY +3.4%, LVS +3.2%, ISIL +3.2%, (light volume), PENN +3.2%, SHOR +3.1%, CMPR +2.6%, POT +2.6%, CL +2.6%, HAR+2.5%, SWK +2.3%, HP +2.2%, F +2%, BEAV +1.7%, BX +1.6%, CRR +1.5%, VLO +1.4%, MEOH +1.3%, VAR +1.2%, CHKP +1.2%, HOLX +1.1%, SSLT +1.1%, GFF +1%, FLS +0.9%, MD +0.9%, MJN +0.9%, CELG +0.9%, PSX +0.9%, RCI +0.8%, JBLU +0.8%
Other news: XNCR +27.1% (eports top-line XmAb5871 Phase 1b/2a results; showing promising clinical activity in Rheumatoid Arthritis), BLDP +10.4% (wins European Union funding for 21 fuel cell buses), VVUS +6.4% (European Commission has amended the marketing authorization for SPEDRA), PSTI +5.9% (cont strength), NBG +5.8% (rebounding after recent weakness), CBRX+5.3% (Chairman Stephen G. Kasnet does not intend to stand for reelection to the Board when his current term expires at the next annual shareholder meeting), BXE +4.3% (updated 2015 net capital budget and operational outlook), ANTH +3.6% (entered into Subscription Agreements with Zenyaku Kogyo and Amgen (AMGN) with respect to a registered direct offering of ~3.2 mln shares of the Company's common stock), MCD +3% (Announced that Don Thompson will retire as President, CEO, and as a member of the Board, effective March 1; Board has elected Steve Easterbrook to replace Thompson as President and CEO), AVP +2.7% (named James S. Scully Chief Financial Officer), FXCM +2.5% (cont pre-mkt vol), SLXP +1.3% (provides update on Audit Committee review; aggregate impact of errors on net product revenue and net income over all previously reported periods affected by the restatements is a decrease of approximately $20.7 mln and $11.9 mln, respectively), MX +1.1% (updates timeline for restatement; expects to file late quarterly and annual reports during the week of February 9, 2015, but no later than February 13, 2015), AZN +1% (announces four research collaborations aimed at harnessing the power of CRISPR), RDHL +0.9% (provides update on progress with RHB-104 ongoing Phase III program)
Analyst comments: TI +3.7% (added to Focus list at Goldman), CYOU +1.9% (upgraded to Overweight from Underweight at HSBC ), AAPL +0.5% (target raised to $135 from $125 at Argus)